Format

Send to

Choose Destination
Clin Infect Dis. 2012 Nov 15;55(10):1392-9. doi: 10.1093/cid/cis731. Epub 2012 Aug 31.

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?

Author information

1
Department of Management Science and Engineering, Stanford University, CA 94305, USA. negoescu@stanford.edu

Abstract

We developed a mathematical model to identify the timing of antiretroviral therapy (ART) initiation that optimizes patient outcomes as a function of patient CD4 count, age, cardiac mortality risk, sex, and personal preferences. Our goal was to find the conditions that maximize patient quality-adjusted life expectancy (QALE) in the context of our model. Under the assumption that ART confers disease progression and mortality benefits at any CD4 count, immediate treatment initiation yields the greatest remaining QALE for young patients under most circumstances. The timing of ART initiation depends on the magnitude of benefit from ART at high CD4 counts, the magnitude of increases in cardiac risk, and patients' preferences. If ART reduces HIV progression at high CD4 counts, immediate ART is preferable for most newly infected individuals <35 years even if ART doubles age- and sex-specific cardiac risk.

PMID:
22942203
PMCID:
PMC3478144
DOI:
10.1093/cid/cis731
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center